CA2695972A1 - Ivig modulation of chemokines for treatment of multiple sclerosis, alzheimer's disease, and parkinson's disease - Google Patents
Ivig modulation of chemokines for treatment of multiple sclerosis, alzheimer's disease, and parkinson's disease Download PDFInfo
- Publication number
- CA2695972A1 CA2695972A1 CA2695972A CA2695972A CA2695972A1 CA 2695972 A1 CA2695972 A1 CA 2695972A1 CA 2695972 A CA2695972 A CA 2695972A CA 2695972 A CA2695972 A CA 2695972A CA 2695972 A1 CA2695972 A1 CA 2695972A1
- Authority
- CA
- Canada
- Prior art keywords
- disease
- multiple sclerosis
- parkinson
- alzheimer
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 208000024827 Alzheimer disease Diseases 0.000 title claims abstract 13
- 208000018737 Parkinson disease Diseases 0.000 title claims abstract 13
- 201000006417 multiple sclerosis Diseases 0.000 title claims 15
- 108010012236 Chemokines Proteins 0.000 title claims 5
- 102000019034 Chemokines Human genes 0.000 title claims 5
- 238000000034 method Methods 0.000 claims abstract 34
- 208000007400 Relapsing-Remitting Multiple Sclerosis Diseases 0.000 claims abstract 14
- 150000001875 compounds Chemical class 0.000 claims abstract 9
- 238000004393 prognosis Methods 0.000 claims abstract 3
- 239000003550 marker Substances 0.000 claims 7
- 239000000523 sample Substances 0.000 claims 6
- 239000003153 chemical reaction reagent Substances 0.000 claims 5
- 102000009410 Chemokine receptor Human genes 0.000 claims 4
- 108050000299 Chemokine receptor Proteins 0.000 claims 4
- 230000000694 effects Effects 0.000 claims 4
- 102100023702 C-C motif chemokine 13 Human genes 0.000 claims 3
- 102100036189 C-X-C motif chemokine 3 Human genes 0.000 claims 3
- 102100036150 C-X-C motif chemokine 5 Human genes 0.000 claims 3
- 102100035298 Cytokine SCM-1 beta Human genes 0.000 claims 3
- 101000978379 Homo sapiens C-C motif chemokine 13 Proteins 0.000 claims 3
- 101000947193 Homo sapiens C-X-C motif chemokine 3 Proteins 0.000 claims 3
- 101000947186 Homo sapiens C-X-C motif chemokine 5 Proteins 0.000 claims 3
- 101000804771 Homo sapiens Cytokine SCM-1 beta Proteins 0.000 claims 3
- 108020004707 nucleic acids Proteins 0.000 claims 3
- 102000039446 nucleic acids Human genes 0.000 claims 3
- 150000007523 nucleic acids Chemical class 0.000 claims 3
- 210000004369 blood Anatomy 0.000 claims 2
- 239000008280 blood Substances 0.000 claims 2
- 102000004169 proteins and genes Human genes 0.000 claims 2
- 108090000623 proteins and genes Proteins 0.000 claims 2
- 102000053642 Catalytic RNA Human genes 0.000 claims 1
- 108090000994 Catalytic RNA Proteins 0.000 claims 1
- 108060003951 Immunoglobulin Proteins 0.000 claims 1
- 108091034117 Oligonucleotide Proteins 0.000 claims 1
- 208000034189 Sclerosis Diseases 0.000 claims 1
- 108020004459 Small interfering RNA Proteins 0.000 claims 1
- 210000001744 T-lymphocyte Anatomy 0.000 claims 1
- 239000012472 biological sample Substances 0.000 claims 1
- 210000004027 cell Anatomy 0.000 claims 1
- 230000005754 cellular signaling Effects 0.000 claims 1
- 210000001175 cerebrospinal fluid Anatomy 0.000 claims 1
- 102000018358 immunoglobulin Human genes 0.000 claims 1
- 238000001990 intravenous administration Methods 0.000 claims 1
- 102000005962 receptors Human genes 0.000 claims 1
- 108020003175 receptors Proteins 0.000 claims 1
- 108091092562 ribozyme Proteins 0.000 claims 1
- 150000003384 small molecules Chemical class 0.000 claims 1
- 229940008228 intravenous immunoglobulins Drugs 0.000 abstract 2
- 210000004556 brain Anatomy 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 208000027866 inflammatory disease Diseases 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/118—Prognosis of disease development
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/136—Screening for pharmacological compounds
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Health & Medical Sciences (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Genetics & Genomics (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Analytical Chemistry (AREA)
- Pathology (AREA)
- Hospice & Palliative Care (AREA)
- Oncology (AREA)
- General Engineering & Computer Science (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Transplantation (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US95561007P | 2007-08-13 | 2007-08-13 | |
| US60/955,610 | 2007-08-13 | ||
| PCT/EP2008/006608 WO2009021708A2 (en) | 2007-08-13 | 2008-08-11 | Ivig modulation of chemokines for treatment of multiple sclerosis, alzheimer's disease, and parkinson's disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2695972A1 true CA2695972A1 (en) | 2009-02-19 |
Family
ID=40259157
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2695972A Abandoned CA2695972A1 (en) | 2007-08-13 | 2008-08-11 | Ivig modulation of chemokines for treatment of multiple sclerosis, alzheimer's disease, and parkinson's disease |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US7968293B2 (enExample) |
| EP (5) | EP2522753B1 (enExample) |
| JP (1) | JP5555626B2 (enExample) |
| AU (1) | AU2008286361B2 (enExample) |
| CA (1) | CA2695972A1 (enExample) |
| ES (5) | ES2477271T3 (enExample) |
| WO (1) | WO2009021708A2 (enExample) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20090280114A1 (en) * | 2002-04-12 | 2009-11-12 | Ramot At Tel Aviv University Ltd. | Prevention of brain inflammation as a result of induced autoimmune response |
| WO2010112034A2 (en) * | 2009-04-02 | 2010-10-07 | Aarhus Universitet | Compositions and methods for treatment and diagnosis of synucleinopathies |
| BRPI1012082B1 (pt) | 2009-05-27 | 2022-08-16 | Takeda Pharmaceutical Company Limited | Método para preparar uma composição de igg concentrada a partir de plasma |
| SG184820A1 (en) * | 2010-04-13 | 2012-11-29 | Baxter Int | Use of ventricular enlargement rate in intravenous immunoglobulin treatment of alzheimer's disease |
| US8796430B2 (en) | 2010-05-26 | 2014-08-05 | Baxter International Inc. | Method to produce an immunoglobulin preparation with improved yield |
| AU2010202125B1 (en) | 2010-05-26 | 2010-09-02 | Takeda Pharmaceutical Company Limited | A method to produce an immunoglobulin preparation with improved yield |
| WO2011150284A2 (en) | 2010-05-26 | 2011-12-01 | Baxter International Inc. | Removal of serine proteases by treatment with finely divided silicon dioxide |
| EP2477032A1 (en) | 2011-01-18 | 2012-07-18 | Baxter International Inc | Measurement of anti-amyloid antibodies in human blood |
| KR20130139153A (ko) | 2011-01-18 | 2013-12-20 | 백스터 인터내셔널 인코포레이티드 | 인간 혈액 중 항-베타 아밀로이드 항체의 측정 |
| US20120251524A1 (en) * | 2011-04-01 | 2012-10-04 | Baxter Healthcare S.A. | Use of cytokine levels in intravenous immunoglobulin treatment of alzheimer's disease |
| PT2791675T (pt) | 2011-12-13 | 2018-07-27 | Baxalta Inc | Medição de autoanticorpos em condições de baixa condutividade |
| WO2014149067A1 (en) | 2013-03-15 | 2014-09-25 | Momenta Pharmaceuticals, Inc. | Methods related to ctla4-fc fusion proteins |
| US10464996B2 (en) | 2013-05-13 | 2019-11-05 | Momenta Pharmaceuticals, Inc. | Methods for the treatment of neurodegeneration |
| US20160257754A1 (en) | 2013-10-16 | 2016-09-08 | Momenta Pharmaceuticals Inc. | Sialylated glycoproteins |
| WO2017070589A1 (en) * | 2015-10-22 | 2017-04-27 | Duke University | Methods and compositions for the diagnosis and treatment of central nervous system autoimmune diseases |
| EP3920887B1 (en) * | 2019-02-04 | 2024-08-14 | The Regents of the University of California | A phosphatidylinositol-glycan-specific phospholipase d1 (gpld1) polypeptide for use in a method of treating or preventing age-related cognitive dysfunction |
| CA3173539A1 (en) | 2020-03-31 | 2021-10-07 | Takeda Pharmaceutical Company Limited | A method to produce an immunoglobulin preparation from c-1 inhibitor depleted plasma |
| EP4490042A1 (en) | 2022-03-08 | 2025-01-15 | Equashield Medical Ltd. | Fluid transfer station in a robotic pharmaceutical preparation system |
| CN116790745A (zh) * | 2023-07-03 | 2023-09-22 | 复旦大学 | 阿尔茨海默病临床前期疾病转化的标志物及其筛选方法 |
| WO2025068923A2 (en) | 2023-09-26 | 2025-04-03 | Takeda Pharmaceutical Company Limited | IMMUNOGLOBULIN FORMULATIONS DEPLETED IN IgA |
| CN119020481A (zh) * | 2024-08-29 | 2024-11-26 | 河络新图生物科技(上海)有限公司 | 检测xcl2基因表达的物质在制备检测帕金森病产品中的应用 |
Family Cites Families (57)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AT376367B (de) | 1983-03-16 | 1984-11-12 | Immuno Ag | Verfahren zur herstellung von therapeutisch verabreichbaren, in endbehaeltern abgefuellten plasmaderivaten |
| DK166763C (da) | 1983-03-16 | 1993-07-12 | Immuno Ag | Immunoglobulin-g-holdig fraktion |
| EP0124506B1 (de) | 1983-05-02 | 1988-08-17 | IMMUNO Aktiengesellschaft für chemisch-medizinische Produkte | Verfahren zur Inaktivierung von vermehrungsfähigen Krankheitserregern |
| AT389815B (de) | 1984-03-09 | 1990-02-12 | Immuno Ag | Verfahren zur inaktivierung von vermehrungsfaehigen filtrierbaren krankheitserregern in blutprodukten |
| US5506337A (en) | 1985-03-15 | 1996-04-09 | Antivirals Inc. | Morpholino-subunit combinatorial library and method |
| AT390560B (de) | 1986-05-30 | 1990-05-25 | Immuno Ag | Verfahren zur inaktivierung von vermehrungsfaehigen filtrierbaren krankheitserregern |
| US4987071A (en) | 1986-12-03 | 1991-01-22 | University Patents, Inc. | RNA ribozyme polymerases, dephosphorylases, restriction endoribonucleases and methods |
| US5010175A (en) | 1988-05-02 | 1991-04-23 | The Regents Of The University Of California | General method for producing and selecting peptides with specific properties |
| GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
| JP2871709B2 (ja) | 1988-11-21 | 1999-03-17 | 住友製薬株式会社 | 免疫グロブリンｇ結合活性を有する新規な蛋白質プロテインｈ、該蛋白質をコードする遺伝子及び該蛋白質の製造法 |
| US5177194A (en) | 1990-02-01 | 1993-01-05 | Baxter International, Inc. | Process for purifying immune serum globulins |
| IE66205B1 (en) | 1990-06-14 | 1995-12-13 | Paul A Bartlett | Polypeptide analogs |
| US5650489A (en) | 1990-07-02 | 1997-07-22 | The Arizona Board Of Regents | Random bio-oligomer library, a method of synthesis thereof, and a method of use thereof |
| US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| KR100272077B1 (ko) | 1990-08-29 | 2000-11-15 | 젠팜인터내셔날,인코포레이티드 | 이종 항체를 생산할 수 있는 전이유전자를 가진 인간이외의 동물 |
| US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| AT402891B (de) | 1991-06-20 | 1997-09-25 | Immuno Ag | Verfahren zur herstellung eines inaktivierten blutproduktes |
| US5573905A (en) | 1992-03-30 | 1996-11-12 | The Scripps Research Institute | Encoded combinatorial chemical libraries |
| US5885527A (en) | 1992-05-21 | 1999-03-23 | Biosite Diagnostics, Inc. | Diagnostic devices and apparatus for the controlled movement of reagents without membrances |
| US5288514A (en) | 1992-09-14 | 1994-02-22 | The Regents Of The University Of California | Solid phase and combinatorial synthesis of benzodiazepine compounds on a solid support |
| WO1994013329A1 (de) | 1992-12-16 | 1994-06-23 | Immuno Aktiengesellschaft | Verfahren zur herstellung eines virussicheren biologischen präparates |
| HRP940645A2 (en) | 1993-10-06 | 1996-12-31 | Immuno Ag | Process for virus deactivation in the presence of polyalkylene glycol and the pharmaceutical preparation thus obtained |
| US5519134A (en) | 1994-01-11 | 1996-05-21 | Isis Pharmaceuticals, Inc. | Pyrrolidine-containing monomers and oligomers |
| US5593853A (en) | 1994-02-09 | 1997-01-14 | Martek Corporation | Generation and screening of synthetic drug libraries |
| US5539083A (en) | 1994-02-23 | 1996-07-23 | Isis Pharmaceuticals, Inc. | Peptide nucleic acid combinatorial libraries and improved methods of synthesis |
| US6447796B1 (en) | 1994-05-16 | 2002-09-10 | The United States Of America As Represented By The Secretary Of The Army | Sustained release hydrophobic bioactive PLGA microspheres |
| US5525735A (en) | 1994-06-22 | 1996-06-11 | Affymax Technologies Nv | Methods for synthesizing diverse collections of pyrrolidine compounds |
| US5549974A (en) | 1994-06-23 | 1996-08-27 | Affymax Technologies Nv | Methods for the solid phase synthesis of thiazolidinones, metathiazanones, and derivatives thereof |
| US5569588A (en) | 1995-08-09 | 1996-10-29 | The Regents Of The University Of California | Methods for drug screening |
| US20020114802A1 (en) | 1998-02-10 | 2002-08-22 | Tjellstrom Bo Arthur Einar | Oral immunoglobulin treatment for inflammatory bowel disease |
| EP1159441B8 (en) | 1999-03-10 | 2008-10-29 | Marie Curie Cancer Care | Delivery of nucleic acids and proteins to cells |
| AU2001273661A1 (en) | 2000-06-30 | 2002-01-14 | Duke University | Methods of screening for alzheimer's disease |
| US20020098182A1 (en) | 2000-09-28 | 2002-07-25 | Richard Weisbart | Treatment of immune-mediated diseases by oral administration of plasma fractions enriched in immunoglobulin G |
| US20020130430A1 (en) | 2000-12-29 | 2002-09-19 | Castor Trevor Percival | Methods for making polymer microspheres/nanospheres and encapsulating therapeutic proteins and other products |
| JP2004532386A (ja) * | 2001-01-26 | 2004-10-21 | オックスフォード グリコサイエンシズ（ユーケー）リミテッド | 多発性硬化症を診断および治療するためのタンパク質、遺伝子、およびこれらの使用 |
| US6905827B2 (en) * | 2001-06-08 | 2005-06-14 | Expression Diagnostics, Inc. | Methods and compositions for diagnosing or monitoring auto immune and chronic inflammatory diseases |
| WO2003028668A2 (en) | 2001-10-04 | 2003-04-10 | Protein Therapeutics, Inc. | Gammaglobulin treatment of immune disorders |
| US7060498B1 (en) | 2001-11-28 | 2006-06-13 | Genta Salus Llc | Polycationic water soluble copolymer and method for transferring polyanionic macromolecules across biological barriers |
| US7442512B2 (en) * | 2001-11-30 | 2008-10-28 | Chemocentryx, Inc. | Compositions and methods for detecting and treating diseases and conditions related to chemokine receptors |
| US7141540B2 (en) | 2001-11-30 | 2006-11-28 | Genta Salus Llc | Cyclodextrin grafted biocompatible amphilphilic polymer and methods of preparation and use thereof |
| US20050222064A1 (en) | 2002-02-20 | 2005-10-06 | Sirna Therapeutics, Inc. | Polycationic compositions for cellular delivery of polynucleotides |
| AU2003214604A1 (en) * | 2002-03-21 | 2003-10-08 | Hadasit Medical Research Services And Development Ltd. | Peripheral blood cell markers useful for diagnosing multiple sclerosis and methods and kits utilizing same |
| US20040014109A1 (en) | 2002-05-23 | 2004-01-22 | Pericak-Vance Margaret A. | Methods and genes associated with screening assays for age at onset and common neurodegenerative diseases |
| AU2003251962A1 (en) | 2002-07-08 | 2004-01-23 | Duke University | Screening for alzheimer's disease |
| US20040204377A1 (en) | 2002-11-26 | 2004-10-14 | University Of Massachusetts | Delivery of siRNAs |
| WO2005027733A2 (en) * | 2003-09-18 | 2005-03-31 | Ppd Biomarker Discovery Sciences, Llc | Biological markers for diagnosing multiple sclerosis |
| WO2005060697A2 (en) | 2003-12-19 | 2005-07-07 | Chiron Corporation | Cell transfecting formulations of small interfering rna, related compositions and methods of making and use |
| JP2007525211A (ja) * | 2004-01-19 | 2007-09-06 | テクニオン リサーチ アンド ディベロップメント ファウンデーション リミテッド | パーキンソン病の診断検査 |
| EP1773998A2 (en) | 2004-04-20 | 2007-04-18 | Nastech Pharmaceutical Company Inc. | Methods and compositions for enhancing delivery of double-stranded rna or a double-stranded hybrid nucleic acid to regulate gene expression in mammalian cells |
| US7514530B2 (en) | 2004-04-26 | 2009-04-07 | Centre National De La Recherche Scientifique | Peptide carrier for delivering siRNA into mammalian cells |
| WO2006077126A2 (en) | 2005-01-19 | 2006-07-27 | Bayer Schering Pharma Aktiengesellschaft | Cx3cr1 as a marker which correlates with both disease and disease activity in multiple sclerosis patients |
| WO2006101925A2 (en) * | 2005-03-16 | 2006-09-28 | Osi Pharmaceuticals, Inc. | Biological markers predictive of anti-cancer response to epidermal growth factor receptor kinase inhibitors |
| US20080045582A1 (en) * | 2006-05-15 | 2008-02-21 | Issam Zineh | ENA-78 Gene Polymorphisms and Protein Concentrations as Diagnostic and Prognostic Tools |
| DE602007013615D1 (de) * | 2006-12-29 | 2011-05-12 | Tel Hashomer Medical Res Infrastructure & Services Ltd | Verfahren und kits zur diagnose von multipler sklerose bei wahrscheinlichen multiple-sklerose-patienten |
| JO3421B1 (ar) | 2011-06-20 | 2019-10-20 | H Lundbeck As | طريقة لإعطاء 1-((1ار.3س)-6-كلورو-3-فينيل-اندان-1-ايل)-1.2.2-ترايميثيل- بيبيرازين واملاجها لمعالجة انفصام الشخصية |
-
2008
- 2008-08-11 EP EP12179739.3A patent/EP2522753B1/en active Active
- 2008-08-11 JP JP2010520478A patent/JP5555626B2/ja not_active Expired - Fee Related
- 2008-08-11 WO PCT/EP2008/006608 patent/WO2009021708A2/en not_active Ceased
- 2008-08-11 ES ES12179736.9T patent/ES2477271T3/es active Active
- 2008-08-11 CA CA2695972A patent/CA2695972A1/en not_active Abandoned
- 2008-08-11 ES ES12179739.3T patent/ES2477292T3/es active Active
- 2008-08-11 ES ES12179740.1T patent/ES2477293T3/es active Active
- 2008-08-11 EP EP12179740.1A patent/EP2522754B1/en active Active
- 2008-08-11 ES ES08785488T patent/ES2416719T3/es active Active
- 2008-08-11 AU AU2008286361A patent/AU2008286361B2/en not_active Ceased
- 2008-08-11 ES ES12179743.5T patent/ES2477294T3/es active Active
- 2008-08-11 EP EP12179743.5A patent/EP2522755B1/en active Active
- 2008-08-11 EP EP12179736.9A patent/EP2522752B1/en active Active
- 2008-08-11 EP EP08785488A patent/EP2191014B1/en active Active
- 2008-08-11 US US12/189,367 patent/US7968293B2/en not_active Expired - Fee Related
-
2011
- 2011-02-11 US US13/026,053 patent/US20110177094A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| US20090148463A1 (en) | 2009-06-11 |
| US7968293B2 (en) | 2011-06-28 |
| EP2522754B1 (en) | 2014-04-02 |
| ES2416719T3 (es) | 2013-08-02 |
| ES2477293T3 (es) | 2014-07-16 |
| ES2477271T3 (es) | 2014-07-16 |
| EP2522755A1 (en) | 2012-11-14 |
| US20110177094A1 (en) | 2011-07-21 |
| AU2008286361A1 (en) | 2009-02-19 |
| ES2477294T3 (es) | 2014-07-16 |
| JP2010535825A (ja) | 2010-11-25 |
| EP2522754A1 (en) | 2012-11-14 |
| WO2009021708A2 (en) | 2009-02-19 |
| EP2522755B1 (en) | 2014-04-02 |
| EP2522753A1 (en) | 2012-11-14 |
| EP2522752A1 (en) | 2012-11-14 |
| JP5555626B2 (ja) | 2014-07-23 |
| WO2009021708A3 (en) | 2009-05-28 |
| AU2008286361B2 (en) | 2013-09-26 |
| EP2522752B1 (en) | 2014-04-02 |
| EP2191014A2 (en) | 2010-06-02 |
| EP2191014B1 (en) | 2013-04-03 |
| EP2522753B1 (en) | 2014-04-02 |
| ES2477292T3 (es) | 2014-07-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2695972A1 (en) | Ivig modulation of chemokines for treatment of multiple sclerosis, alzheimer's disease, and parkinson's disease | |
| JP7054990B2 (ja) | 炎症性腸疾患の診断及び治療のための方法 | |
| KR101845552B1 (ko) | 뇌손상 질환 진단용 마커로서의 Ｌｉｎ-28의 용도 | |
| WO2007112097A2 (en) | Novel signature self renewal gene expression programs | |
| CA2938731A1 (en) | Methods of treating alzheimer's disease | |
| JP2017507130A5 (enExample) | ||
| JP2014014370A (ja) | インターフェロンα誘導性薬力学的マーカー | |
| WO2008137838A2 (en) | Interferon alpha-induced pharmacodynamic markers | |
| EP2297357B1 (en) | Prediction of antiviral therapy response | |
| RU2015147287A (ru) | Гуманизированные антитела против axl | |
| MX2015003932A (es) | Metodos para diagnosticar y tratar la enfermedad inflamatoria intestinal. | |
| Monaghan et al. | CSL362 potently and specifically depletes pDCs in vitro and ablates SLE-immune complex-induced IFN responses | |
| Nagy et al. | STAT5 regulation of BCL10 parallels constitutive NFκB activation in lymphoid tumor cells | |
| KR20180109811A (ko) | 항암 치료 내성 판단 방법 및 상기 방법에 사용되는 조성물 | |
| US20220105122A1 (en) | Therapeutic and prophylactic agent for glioma, brain tumor malignancy marker, brain tumor prognostic marker, method for determining malignancy and prognosis of brain tumor and antibody inhibiting tumor proliferation | |
| Banham et al. | B‐cell biomarkers in transplantation–from genes to therapy | |
| US20200024667A1 (en) | Mirna based treatment monitoring in multiple sclerosis | |
| DK1989323T3 (da) | Diagnostiske fremgangsmåder der involverer bestemmelse af genkopiantal og SNP'er i Fc RII/Fc-RIII-genklynger og prøver til anvendelse i sådanne fremgangsmåder til at detektere modtagelighed for og behandlingseffektivitet i autoimmune sygdomme | |
| US20220091104A1 (en) | Analysis of polymorphisms in sirp-alpha for evaluating response to immunotherapy | |
| KR101390611B1 (ko) | 뇌성마비 질환 진단용 마커로서 Ｌｉｎ-28의 용도 | |
| US20160194712A1 (en) | Mirna based treatment monitoring in autoimmune diseases | |
| WO2011088219A2 (en) | Therapeutics and processes for treatment of immune disorders | |
| US20210062273A1 (en) | Methods for rapid detection of egfr variants and amplification | |
| WO2016141441A1 (en) | Treatment and detection of inflammatory disease | |
| EP4572854A2 (en) | Anti-axl antibodies, antigen-binding fragments thereof and methods for making and using the same |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FZDE | Discontinued |